Cellectis S.A.
CMVLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.07 | -0.03 | 0.86 |
| FCF Yield | 14.09% | -15.15% | -94.88% | -34.20% |
| EV / EBITDA | -5.55 | -1.28 | -0.95 | -3.35 |
| Quality | ||||
| ROIC | -25.84% | -56.67% | -42.52% | -22.03% |
| Gross Margin | 100.00% | 2.38% | 90.76% | 50.95% |
| Cash Conversion Ratio | -0.63 | 0.21 | 0.89 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.37% | -78.31% | -36.24% | 69.48% |
| Free Cash Flow Growth | 174.15% | 71.28% | 27.69% | 1.75% |
| Safety | ||||
| Net Debt / EBITDA | 3.42 | 0.56 | 0.29 | 1.03 |
| Interest Coverage | -7.99 | -16.59 | -5.39 | -16.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 202.59 | 1,738.11 | -4,084.95 | -85.72 |